Global chronic lymphocytic leukemia market was worth USD 2.2 billion in 2015. It is expected to grow at a CAGR of 20% from 2016 to 2020 (forecast period).
Leukemia is a type of cancer that begins in the blood-forming cells of the bone marrow, gradually spreading to other regions. Chronic lymphocytic leukemia (CLL) has its origins in the white blood cells or lymphocytes within the bone marrow. CLL is of chronic nature and primarily affects the elderly.
Rising incidence of chronic lymphocytic leukemia across the world is said to boost market growth. The growing patient awareness regarding the illness and its treatment options could increase adoption rates till 2020.
Browse Detail Report With TOC @ http://www.hexareports.com/report/global-chronic-lymphocytic-leukemia-market-2016-2020/details
Factors like unmet medical needs and special provisions to orphan drugs are also creating a favorable impact. In the European Union, orphan drugs enjoy market-exclusivity for 10 years and are given protocol assistance. The U.S. grants incentives such as tax credits for clinical testing, and exemptions from prescription drug user fees.
The recent drug approvals could also have a positive effect on market demand. Imbruvica, Gazyva, IPI-145, and idealisib are some of the branded drugs in the pipeline. Imbruvica and idealisib in particular, exhibit strong efficacy and tolerability during the trial phases.
However, the treatment of CLL is highly expensive. Moreover, the drugs have adverse side effects. The availability of off-label drugs and chemotherapy also pose a challenge to market growth.
The worldwide chronic lymphocytic leukemia market is categorized on the basis of molecule type, ROA, and geographies. Molecules are divided into small molecules and biologics. ROA is either oral or parenteral.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/132310
Geographies comprise the Americas, EMEA (Europe, Middle East & Africa), and APAC (Asia Pacific). In North America, the U.S. is the leading regional market. Germany dominates in Europe. North America and Europe will generate high demand owing to genetic predisposition of their populace to CLL.
Novartis, AbbVie, Johnson & Johnson, Teva Pharmaceuticals, Gilead Sciences, F. Hoffman-La Roche, and Xeme Biopharma are the prominent market players. Joint ventures and partnerships are some of the key trends prevalent in the market. Combination therapies are expected to rise in popularity in the coming years. TG-1101 was developed to treat CLL in combination with ibrutinib by TG Therapeutics.
Related Reports:
Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020:
http://www.hexareports.com/report/global-chronic-obstructive-pulmonary-disease-drugs-market-2016-2020/details
Global Enteric Disease Testing Market 2016-2020:
http://www.hexareports.com/report/global-enteric-disease-testing-market-2016-2020/details
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Media Contact
Company Name: Hexa Reports
Contact Person: Ryan Shaw
Email: sales@hexareports.com
Phone: 1-800-489-3075
Address:Felton Office Plaza, 6265 Highway 9
City: Felton
State: California
Country: United States
Website: http://www.hexareports.com/report/global-chronic-lymphocytic-leukemia-market-2016-2020/details